REG - BioPharma Credit PLC - Dividend Declaration

Biopharma CreditAnnouncement

18/09/2025 17:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250918:nRSR9518Za&default-theme=true

RNS Number : 9518Z  BioPharma Credit PLC  18 September 2025

18 September 2025

 

BIOPHARMA CREDIT PLC

("BIOPHARMA CREDIT" OR THE "COMPANY")

ORDINARY AND SPECIAL DIVIDEND DECLARATION

3.25 CENT PER SHARE DISTRIBUTION INCLUDING A 1.50 CENT SPECIAL DISTRIBUTION

6.75 CENTS PER SHARE DECLARED IN 2025 TO DATE

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor,
is pleased to declare an increased interim dividend of 3.25 cents per share in
respect of the quarterly financial period ending 30 September 2025, payable on
31 October 2025 to ordinary shareholders on the register as at 26 September
2025. The ex-dividend date will be 25 September 2025.

The Company aims to generate long-term shareholder returns, predominantly in
the form of sustainable income distributions from its investments in the life
sciences industry.  The Company currently pays, and continues to target, a
7-cent base annual dividend per ordinary share in four quarterly payments of
1.75 cents per share. Typically, these are supplemented by excess income in
the form of special dividend distributions in Q4 and in some years, Q3 and Q4
where the Board determines that it is appropriate and able to do so (noting
the requirement to pay out substantially all income to maintain the Company's
investment trust status).

After the payment of the interim dividend on 31 October 2025, dividends for
the calendar year 2025 to date will total 6.75 cents. Total dividends paid
since IPO to date will total 73.68 cents.

Dividends in recent years:

 Financial year (ending 31 December)  Amount (US cents)
 Year to Date 2025                    6.75
 2024                                 10.18
 2023                                 10.21
 2022                                 13.08

By way of reference, the Company's shares traded as of 17 September 2025 at a
price of 91 cents.

The default payment for dividends is in US dollars. However, shareholders can
elect to have dividends paid in sterling (GBP) and the option to elect a
sterling dividend payment for this dividend will be available to shareholders
until 26 September 2025 (being the "Election Date").

The Company has chosen to designate the entire amount of this interim dividend
as an interest distribution. Shareholders in receipt of such a dividend will
be treated for UK tax purposes as though they have received a payment of
interest. This will result in a reduction in the corporation tax payable by
the Company.

A copy of the Dividend Currency Election Form, which should be sent to MUFG
Corporate Markets, 19(th) Floor, 51 Lime Street, London EC3M 7DQ when
completed, will be available on the Company's website
at www.bpcruk.com/investor-materials
(http://www.bpcruk.com/investor-materials) . CREST shareholders must elect via
CREST.

Enquiries:

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

Burson Buchanan

Mark Court / Jamie Hooper / Henry Wilson / Nick Croysdill

+44 (0) 20 7466 5000

biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com)

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from
the life sciences industry and joined the LSE on 27 March 2017. The Company
seeks to provide long-term shareholder returns, principally in the form of
sustainable income distributions from exposure to the life sciences industry.
The Company seeks to achieve this objective primarily through investments in
debt assets secured by royalties or other cash flows derived from the sales of
approved life sciences products.

LEI: 213800AV55PYXAS7SY24

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DIVLPMFTMTBBBTA